Lifeward Ltd. (LFWD)
NASDAQ: LFWD · Real-Time Price · USD
0.730
+0.030 (4.34%)
At close: Dec 5, 2025, 4:00 PM EST
0.760
+0.030 (4.05%)
After-hours: Dec 5, 2025, 7:59 PM EST
Lifeward Revenue
Lifeward had revenue of $6.20M in the quarter ending September 30, 2025, with 1.09% growth. This brings the company's revenue in the last twelve months to $24.50M, down -2.02% year-over-year. In the year 2024, Lifeward had annual revenue of $25.66M with 85.24% growth.
Revenue (ttm)
$24.50M
Revenue Growth
-2.02%
P/S Ratio
0.35
Revenue / Employee
$306,225
Employees
80
Market Cap
12.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.66M | 11.81M | 85.24% |
| Dec 31, 2023 | 13.85M | 8.34M | 151.39% |
| Dec 31, 2022 | 5.51M | -455.00K | -7.63% |
| Dec 31, 2021 | 5.97M | 1.57M | 35.81% |
| Dec 31, 2020 | 4.39M | -480.00K | -9.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LFWD News
- 2 days ago - Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval - GlobeNewsWire
- 18 days ago - UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton - GlobeNewsWire
- 21 days ago - Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Lifeward Ltd. Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 25 days ago - Lifeward to Report Third Quarter Financial Results on November 14, 2025 - GlobeNewsWire
- 3 months ago - First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton - GlobeNewsWire
- 3 months ago - Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton - GlobeNewsWire
- 4 months ago - Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript - Seeking Alpha